

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Antisense Therapeutics Limited

**ABN**

41 095 060 745

**Quarter ended ("current quarter")**

30<sup>th</sup> June 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(302)	(1,437)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(35)	(86)
(d) leased assets	-	-
(e) staff costs	(275)	(973)
(f) administration and corporate costs	(172)	(805)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	18	73
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (R&D Tax Concession refund)	-	285
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(766)</b>	<b>(2,943)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	1,602
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(55)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (Proceeds from issue of options)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>1,547</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	3,670	4,300
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(766)	(2,943)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	1,547

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>2,904</b>	<b>2,904</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	404	370
5.2	Call deposits	2,500	3,300
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above) **</b>	<b>2,904</b>	<b>3,670</b>

**\*\*Note: The Company anticipates receiving an R&D Tax incentive refund later in this calendar year in relation to R&D expenditure for the year ending 30 June 2019 (including that associated with the ongoing clinical trial of ATL1102 in DMD).**

**6. Payments to directors of the entity and their associates**

- |     | <b>Current quarter<br/>\$A'000</b> |
|-----|------------------------------------|
| 6.1 | 173                                |
| 6.2 | -                                  |
| 6.3 |                                    |

Item 6.1 reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).

**7. Payments to related entities of the entity and their associates**

- |     | <b>Current quarter<br/>\$A'000</b> |
|-----|------------------------------------|
| 7.1 | -                                  |
| 7.2 | -                                  |
| 7.3 |                                    |

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--	--

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	300
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	20
9.4 Leased assets	-
9.5 Staff costs	290
9.6 Administration and corporate costs	230
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows **</b>	<b>840</b>

\*\* Cash outflow for the next quarter may vary from the estimate depending on available resources, the priority of projects and their status and opportunities as they evolve.

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here: ..... Date: Thursday 18 July 2019  
(Director/Company secretary)

Print name: **Phillip Hains**  
Company Secretary



18<sup>th</sup> July 2019

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.